MR13A9 + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Uremic Pruritus
Conditions
Uremic Pruritus
Trial Timeline
Jan 16, 2021 → Sep 26, 2022
NCT ID
NCT04711603About MR13A9 + Placebo
MR13A9 + Placebo is a phase 3 stage product being developed by Kissei Pharmaceutical for Uremic Pruritus. The current trial status is completed. This product is registered under clinical trial identifier NCT04711603. Target conditions include Uremic Pruritus.
What happened to similar drugs?
0 of 6 similar drugs in Uremic Pruritus were approved
Approved (0) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04711603 | Phase 3 | Completed |
| NCT03802617 | Phase 2 | Completed |
Competing Products
15 competing products in Uremic Pruritus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 44 |
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 44 |
| Ravulizumab | AstraZeneca | Pre-clinical | 33 |
| Eculizumab | AstraZeneca | Phase 3 | 40 |
| Iptacopan | Novartis | Phase 3 | 44 |
| Iptcaopan 200 mg | Novartis | Phase 3 | 47 |
| Iptacopan | Novartis | Phase 3 | 47 |
| MR13A9 + Placebo | Kissei Pharmaceutical | Phase 2 | 35 |
| CCX168 | Amgen | Phase 2 | 27 |
| Stage I:HSK21542 0.05 μg/kg + Stage I:HSK21542 0.15 μg/kg + Stage I:HSK21542 0.30 μg/kg + Stage I:HSK21542 0.80 μg/kg + Stage II:HSK21542 0.3 μg/kg + Stage II:HSK21542 0.6 μg/kg | Haisco Pharmaceutical Group | Phase 2 | 35 |
| Cemdisiran | Alnylam Pharmaceuticals | Phase 2 | 24 |
| cemdisiran + Placebos | Alnylam Pharmaceuticals | Phase 2 | 24 |
| nalbuphine HCl ER | Trevi Therapeutics | Phase 2/3 | 32 |
| Nalbuphine HCL ER | Trevi Therapeutics | Phase 1 | 23 |
| nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BID | Trevi Therapeutics | Phase 2/3 | 32 |